Overview

KLOW is Helyxlab’s proprietary 80mg research blend combining BPC-157 and GHK-Cu in a single lyophilised vial. These two compounds were selected together because their mechanisms are non-overlapping — they address different levels of the same biological goal. BPC-157 targets the acute, local, structural conditions at the site of damage. GHK-Cu targets the broader cellular and genetic environment across multiple systems simultaneously. One creates the conditions for repair. The other amplifies and sustains the capacity to carry it out.

What it does

BPC-157 drives angiogenesis and collagen synthesis acutely — increasing blood supply, growth hormone receptor expression in fibroblasts, and structural repair signalling at the administration site. GHK-Cu simultaneously shifts the expression of 4,000+ genes toward regeneration — upregulating collagen production, fibroblast activity, anti-inflammatory pathways, antioxidant defences, and DNA repair while downregulating pro-inflammatory and pro-fibrotic gene expression. Administered together, they operate in parallel rather than in competition — the acute structural driver and the systemic cellular reset, in a single injection.

Research areas

Acute musculoskeletal injury — tendon, ligament, muscle, joint · Gastrointestinal repair and gut lining integrity · Post-injury and post-procedure recovery research · Skin and connective tissue regeneration · Anti-aging and systemic cellular regeneration · Chronic inflammatory conditions research

Key facts

For research use only. Not for human consumption. This product is not approved for human use by the FDA or any regulatory body.